Suramin: A Comprehensive Pharmacological and Therapeutic Review

1. Executive Summary

Suramin is a complex, polyanionic symmetrical urea derivative with a storied history spanning over a century. Originally developed in the early 20th century primarily for the treatment of parasitic diseases, notably Human African Trypanosomiasis (HAT) and onchocerciasis, its unique chemical structure and multifaceted interactions with biological systems have led to its investigation for a remarkably diverse array of other conditions, including various cancers, viral infections, and, more recently, neurodevelopmental disorders such as Autism Spectrum Disorder (ASD).[1]

The pharmacological profile of suramin is characterized by its polypharmacology, interacting with a multitude of molecular targets rather than a single specific receptor or enzyme. This broad activity underpins its potential in diverse therapeutic areas but also contributes to its significant and often dose-limiting toxicity profile.[1] Key pharmacokinetic features include its parenteral route of administration (due to poor oral bioavailability), extensive plasma protein binding, and an exceptionally long elimination half-life, which necessitates careful dosing and monitoring to avoid accumulation and toxicity.[1]

While suramin remains a crucial drug for early-stage HAT caused by Trypanosoma brucei rhodesiense and is listed as a WHO Essential Medicine [4], its use in onchocerciasis has largely been superseded by safer alternatives.[6] Its potent antineoplastic properties have been demonstrated in preclinical models and some clinical trials, but development for many cancers has been hampered by its toxicity.[7] The exploration of suramin for ASD, based on its antipurinergic activity, represents a novel application of an old drug, with early clinical data showing promise.[8] Furthermore, its broad-spectrum antiviral activity, including against SARS-CoV-2 in vitro, continues to attract research interest.[10]

Recent research has focused on developing new formulations, such as intranasal suramin (e.g., PAX-102 by PaxMedica), to potentially improve CNS delivery and reduce systemic side effects for neurological indications.[12] Additionally, efforts to synthesize suramin analogues aim to enhance therapeutic efficacy while mitigating its inherent toxicities.[14]

Suramin's journey from an early 20th-century antiparasitic to a candidate for modern complex diseases like autism and viral infections illustrates a recurring pattern in pharmacology: established drugs can find new therapeutic life as scientific understanding of their mechanisms evolves. However, the historical limitations of such molecules, particularly toxicity, remain critical challenges that must be addressed through innovative pharmaceutical strategies. The enduring relevance of suramin, therefore, lies in this balance between its multifaceted therapeutic potential and the significant hurdles to its safe and effective broader application.

2. Introduction to Suramin

2.1. Historical Background and Discovery

Suramin, a complex synthetic compound, was developed in 1916 by Oskar Dressel, Richard Kothe, and Bernhard Heymann at Bayer in Germany, and subsequently marketed under the trade name Germanin®.[1] Its development stemmed from research into derivatives of the dye trypan blue, which had shown some antiparasitic activity.[2] Suramin was one of the earliest examples of a drug developed through a systematic medicinal chemistry program, marking a significant step in the evolution of chemotherapy.[2]

Interestingly, the chemical formula of suramin was initially kept secret by Bayer for commercial reasons. It was not until 1924 that Ernest Fourneau and his colleagues at the Pasteur Institute in France elucidated and published its structure, making its exact chemical composition publicly known.[16] This period of secrecy and subsequent independent discovery reflects the competitive pharmaceutical landscape and the intense scientific drive for therapeutic breakthroughs in the early 20th century, even amidst prevailing geopolitical tensions. Such dynamics undoubtedly shaped the early control and dissemination of this important medication.

2.2. Significance and Overview of Therapeutic Potential

The introduction of suramin was a major advancement in the treatment of Human African Trypanosomiasis (HAT), also known as sleeping sickness, a devastating disease prevalent in many parts of Africa.[2] As a polyanionic compound, suramin exhibits a broad, though not always fully understood, spectrum of biological activities.[1] Its therapeutic potential, demonstrated over more than a century of use and investigation, extends beyond its initial antiparasitic applications to include antineoplastic, antiviral, and, more recently, potential neuro-modulatory effects.[1]

The drug's longevity and the continued scientific interest in its properties underscore its unique chemical characteristics and its capacity to interact with a wide range of biological systems. The "enigmatic" nature of suramin, with its numerous molecular targets and, for a long time, unclear cellular uptake mechanisms for some effects [2], suggests that many of its later-explored therapeutic applications may have arisen from serendipitous observations or broad empirical screening rather than from targeted drug design for those specific indications. This polypharmacology, while offering diverse therapeutic avenues, is intrinsically linked to its complex and often challenging side effect profile, a characteristic that has significantly influenced its clinical utility and ongoing research efforts.

3. Chemical Profile and Pharmaceutical Formulation

3.1. Nomenclature

The generically recognized name for this compound is Suramin [User Query]. It is most commonly available and administered as its hexasodium salt, Suramin Sodium, a form which enhances its water solubility.[5] Throughout its long history, suramin has been known by various synonyms and trade names, including Germanin® (the original Bayer trade name), Bayer 205, Antrypol, Moranyl, Naganin, Naganine, CI-1003, and 309 Fourneau.[1]

3.2. Chemical Structure and Physicochemical Properties

Suramin is a large, symmetrical, polyanionic molecule belonging to the class of phenylureas, specifically a naphthylurea. Its structure is characterized by a central urea group linking two identical, complex side chains, each containing multiple aromatic rings (benzene and naphthalene moieties) and three sulfonic acid groups, totaling six sulfonic acid groups per molecule.[1]

The molecular formula for the free acid form of suramin is C51​H40​N6​O23​S6​.[19] Its molecular weight is approximately 1297.3 g/mol for the free acid and 1429.19 g/mol for the hexasodium salt.[19] The IUPAC name for suramin is 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid, or similar complex systematic names reflecting its intricate structure.[1] Standard chemical identifiers such as SMILES and InChIKey are available in chemical databases.[1]

The physicochemical properties of suramin are largely dictated by its polyanionic nature. This high density of negative charges at physiological pH is key to its interactions with many biological macromolecules.[1] The sodium salt form is soluble in water, sparingly soluble in alcohol, and practically insoluble in nonpolar organic solvents like benzene, ether, or chloroform.[20] The octanol-water partition coefficient (LogP) values reported vary (e.g., 0.9 for the sodium salt by ALOGPS, 9.11 by Chemaxon for the sodium salt, and XLogP 0.91 for the free acid).[20] Such discrepancies likely reflect the inherent difficulty in applying traditional LogP concepts, designed for neutral, lipophilic compounds, to a large, highly charged molecule like suramin sodium. For suramin, electrostatic interactions and solvation in aqueous environments are more dominant determinants of its behavior than simple lipophilicity. Its strongest acidic pKa is very low (around -3.5, Chemaxon), indicating that the sulfonic acid groups are fully ionized at physiological pH.[20] It possesses a high number of hydrogen bond acceptors (around 29) and donors (6-12, depending on the source and whether the acid or salt form is considered).[20] The polar surface area is consequently very large, reported as 518.18 A˚2 to 534.03 A˚2.[20] Suramin is hygroscopic, and the sodium salt is known to deteriorate rapidly in air, necessitating careful storage.[21]

The strong polyanionic character and substantial molecular size of suramin are fundamental to its overall pharmacological profile. These characteristics govern its poor permeability across biological membranes, which necessitates intravenous administration and results in low oral bioavailability.[25] Furthermore, these properties contribute to its high degree of plasma protein binding and its capacity to interact with a diverse array of biological targets, particularly positively charged domains on proteins such as enzymes, receptors, and growth factors, thereby explaining its observed polypharmacology.[2]

3.3. Available Formulations

Suramin is primarily available as a sterile powder for injection, usually as suramin sodium in 1g vials. This powder is reconstituted with a suitable diluent (e.g., sterile water for injection) to form a solution for slow intravenous (IV) administration.[5] Due to its poor absorption from the gastrointestinal tract, suramin is not orally bioavailable, making parenteral administration essential for systemic effects.[1] Administration via intramuscular or subcutaneous routes is generally avoided as it can lead to local tissue inflammation or necrosis.[25]

In addition to the conventional IV formulation, investigational formulations are being explored. Notably, PaxMedica is developing an intranasal formulation of suramin, designated PAX-102, primarily for potential applications in neurological disorders such as ASD.[12]

Table 1: Suramin - Key Identifiers and Chemical Properties

Property	Value	Snippet(s) Reference(s)
IUPAC Name	8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid (representative for free acid)	1
CAS Number	145-63-1 (Suramin free acid)	User Query, 19
	129-46-4 (Suramin hexasodium salt)	19
DrugBank ID	DB04786	User Query
Molecular Formula	C51​H40​N6​O23​S6​ (free acid)	19
	C51​H34​N6​Na6​O23​S6​ (hexasodium salt)	21
Molecular Weight	~1297.3 g/mol (free acid)	19
	~1429.19 g/mol (hexasodium salt)	21
Key Synonyms	Germanin®, Bayer 205, Antrypol, Moranyl	1
Appearance	White crystalline powder (sodium salt)	21
Solubility (Sodium Salt)	Soluble in water; sparingly soluble in alcohol; insoluble in benzene, ether, chloroform	20
LogP (Sodium Salt)	0.9 (ALOGPS); 9.11 (Chemaxon)	20
pKa (Strongest Acidic)	~ -3.5 (Chemaxon)	20
Polar Surface Area	518.18 A˚2 - 534.03 A˚2	20
Hydrogen Bond Acceptors	29 (Chemaxon, for sodium salt)	20
Hydrogen Bond Donors	6 (Chemaxon, for sodium salt); 12 (CDK, for free acid)	20
Stability Notes	Hygroscopic; sodium salt deteriorates rapidly in air	21

4. Pharmacology

4.1. Mechanism of Action

The mechanism of action of suramin is exceptionally complex and has often been described as unknown or not fully elucidated in earlier literature.[1] However, extensive research has revealed that suramin does not act via a single, specific target. Instead, it exhibits a polypharmacological profile, interacting with a multitude of molecular targets within host and pathogen cells. This broad interactivity is largely attributed to its polyanionic structure, which facilitates binding to various proteins, including enzymes, receptors, and growth factors.[1]

4.1.1. Trypanocidal and Antifilarial Mechanisms

African Trypanosomiasis (Sleeping Sickness):

Suramin's efficacy against trypanosomes, the causative agents of African sleeping sickness, involves several mechanisms:

• Enzyme Inhibition: It is thought to inhibit enzymes crucial for the parasite's metabolism, particularly those involved in the oxidation of reduced nicotinamide-adenine dinucleotide (NADH), a coenzyme vital for cellular respiration and glycolysis in trypanosomes.[1]
• Cellular Uptake and Accumulation: Suramin accumulates rapidly within trypanosome cells. This uptake appears to be, at least in part, mediated by the Invariant Surface Glycoprotein 75 (ISG75), with accumulation levels proportional to ISG75 abundance, suggesting a receptor or transporter role for this protein.[2] The rapid uptake contrasts with the relatively slow killing action of the drug, implying a protracted disruption of cellular functions rather than immediate blockade of a single vital process.[27]
• Metabolic and Mitochondrial Disruption: Studies indicate that suramin exposure alters the cellular metabolism and mitochondrial energy production in African trypanosomes.[27]
• Inhibition of Cytokinesis: In Trypanosoma brucei, suramin has been shown to inhibit cytokinesis (cell division).[14] The presence of methyl groups on the intermediate rings of the suramin molecule and the specific regiochemistry of its naphthalenetrisulphonic acid groups are critical for this trypanocidal activity and its specific mode of action.[14] A significant limitation for its use in HAT is that suramin does not effectively cross the blood-brain barrier at standard therapeutic doses, restricting its utility to the early (hemolymphatic) stage of the disease, before the parasites have invaded the central nervous system.[2]

Onchocerciasis (River Blindness):

In the treatment of onchocerciasis, caused by the filarial nematode Onchocerca volvulus, suramin acts as a macrofilaricide, meaning it kills the adult worms, and also exhibits partial microfilaricidal activity against the larval stages.1 One proposed mechanism involves damage to the intestinal epithelium of the worms.43

4.1.2. Antineoplastic Mechanisms

Suramin has demonstrated potent antineoplastic properties through various mechanisms:

• Inhibition of Tumor Growth and Angiogenesis: It can inhibit tumor growth and the formation of new blood vessels (angiogenesis) that tumors require to grow.[1]
• Antagonism of Growth Factors and Receptors: Suramin interacts with and inhibits numerous growth factors and their signaling pathways, which are often dysregulated in cancer:
• Platelet-Derived Growth Factor (PDGF): Suramin binds to PDGF, preventing its interaction with its receptor, thereby inhibiting its biological activity and blocking PDGF-induced tyrosine phosphorylation, a key step in cell signaling.[5]
• Epidermal Growth Factor Receptor (EGFR): The interaction with the EGFR pathway is complex. In some cancer cell lines, such as A431 epidermoid carcinoma cells, suramin has been shown to indirectly activate EGFR signaling. It achieves this by inducing the release of membrane-bound Transforming Growth Factor-alpha (TGF-α), a ligand for EGFR, which then activates the receptor.[48] This effect is somewhat counterintuitive for an anticancer agent and contrasts with its inhibitory effects on other growth factor pathways like PDGF. The net effect of suramin on tumor growth may, therefore, be highly dependent on the specific balance of growth factor pathways active in a particular tumor type. This complexity could contribute to the variable efficacy observed in different cancers.
• Insulin-like Growth Factor I (IGF-I): Suramin binds to IGF-I.[5] In certain breast cancer cell lines, sensitivity to suramin has been correlated with the expression levels of the IGF-I receptor (IGFR).[53]
• Basic Fibroblast Growth Factor (bFGF) and Vascular Endothelial Growth Factor (VEGF): Suramin inhibits angiogenesis induced by bFGF and VEGF, both of which are critical mediators of new blood vessel formation in tumors.[5]
• Enzyme Inhibition: Suramin inhibits various enzymes that are crucial for cancer cell development and proliferation. These include heparanase, an enzyme involved in extracellular matrix degradation and metastasis [19]; topoisomerases, which are involved in DNA replication and repair [5]; and telomerase, an enzyme that maintains telomere length and is often reactivated in cancer cells, contributing to their immortality.[16]
• Direct Antiproliferative Effects: Suramin has demonstrated direct antiproliferative effects against a range of cancer cell lines, including ovarian, cervical, breast, and glioma cells.[19]
• Chemosensitization: There is some evidence suggesting that suramin may act as a chemosensitizer, potentially enhancing the efficacy of other anticancer drugs when used in combination.[2]

4.1.3. Antiviral Mechanisms

Suramin has been reported to possess broad-spectrum antiviral activity.[2] Its antiviral mechanisms are diverse and include:

• Inhibition of Viral Entry/Attachment: Suramin can interfere with the initial stages of viral infection by blocking the binding of viruses to host cells or their subsequent entry. This has been observed for viruses such as dengue virus, herpes simplex virus, and hepatitis C virus.[2]
• Inhibition of Viral Enzymes:
• Reverse Transcriptase: Suramin is known to inhibit retroviral reverse transcriptase, an enzyme essential for the replication of retroviruses like HIV.[2]
• SARS-CoV-2 RNA-dependent RNA polymerase (RdRp): Suramin binds directly to the SARS-CoV-2 RdRp, the enzyme responsible for replicating the viral RNA genome. This binding blocks the RNA template from accessing the active site and prevents the entry of product RNA, thereby inhibiting viral replication.[10] In vitro studies have shown that suramin inhibits SARS-CoV-2 replication in cell culture with a half-maximal effective concentration (EC50) of approximately 20 µM.[11]
• Inhibition of Viral Replication Steps: It has been shown to inhibit RNA synthesis and replication in Chikungunya virus.[2]

4.1.4. Other Molecular Targets and Mechanisms

Suramin's polypharmacology extends to numerous other molecular targets:

• P2 Purinergic Receptor Antagonist: Suramin acts as a broad-spectrum antagonist of P2 purinergic receptors.[1] This is a key mechanism being explored for its potential therapeutic effects in Autism Spectrum Disorder, based on the Cell Danger Response (CDR) hypothesis, which implicates dysregulated purinergic signaling in the pathophysiology of ASD.[9]
• Ryanodine Receptor (RyR) Agonist: It activates ryanodine receptors, specifically the RyR1 (skeletal muscle) and RyR2 (cardiac) isoforms, which are intracellular calcium release channels.[1]
• Protein-Tyrosine Phosphatase (PTPase) Inhibitor: Suramin is a reversible and competitive inhibitor of PTPases.[10]
• Sirtuin Inhibitor: It is a potent inhibitor of sirtuins, including SirT1, SirT2, and SirT5, which are NAD+-dependent deacetylases involved in various cellular processes.[3]
• Follicle-Stimulating Hormone (FSH) Receptor Inhibitor: Suramin can inhibit FSH receptors.[1]
• G Protein Signaling: It can inhibit the coupling of G proteins to G protein-coupled receptors (GPCRs), thereby modulating downstream signaling pathways.[5]
• Antibacterial Activity (RecA Inhibition): Suramin is a potent inhibitor of bacterial RecA proteins, such as that from Mycobacterium tuberculosis. It acts by disassembling RecA-single-stranded DNA (ssDNA) filaments, which are essential for DNA repair and the SOS response in bacteria. By inhibiting RecA, suramin can block the SOS response and has been shown to augment the bactericidal action of other antibiotics like ciprofloxacin.[29]
• Inositol Pentakisphosphate Kinase (IP5K) Inhibition: Suramin efficiently inhibits IP5K.[10]
• Enzyme Inhibition Relevant to Snakebite: It inhibits thrombin and phospholipase A2, components often found in snake venoms, suggesting a potential application as a snakebite antivenom.[2]

4.2. Pharmacokinetics

The pharmacokinetic profile of suramin is characterized by poor oral absorption, extensive plasma protein binding, limited metabolism, renal excretion, and a very long elimination half-life.

• Absorption: Suramin is poorly absorbed from the gastrointestinal tract. Consequently, it must be administered parenterally, typically via slow intravenous (IV) infusion, to achieve systemic therapeutic concentrations.[1]
• Distribution:
• Protein Binding: Suramin is highly bound to plasma proteins, with reported binding percentages around 99-99.7%, primarily to albumin.[3] This extensive protein binding significantly influences its distribution and contributes to its long half-life and limited diffusion into certain tissues.
• Volume of Distribution (Vd): The volume of distribution for suramin in humans has been reported to be in the range of 31-46 liters.[33] This relatively low Vd, considering its high protein binding, suggests that its distribution is largely confined to the vascular and extracellular fluid compartments.
• CNS Penetration: Suramin does not distribute well into the cerebrospinal fluid (CSF) at standard therapeutic doses used for early-stage HAT.[2] This poor CNS penetration is a critical factor limiting its efficacy in treating late-stage HAT where parasites have invaded the central nervous system.
• Metabolism: Suramin undergoes little to no metabolism in the body.[1] It is a chemically stable molecule that is largely excreted unchanged.
• Excretion:
• The primary route of elimination for suramin is via the kidneys, with the drug being excreted unchanged in the urine.[25] Approximately 80% of an administered dose is eventually eliminated through renal excretion.[25]
• Urinary excretion is a slow process. One study reported that less than 4% of the administered dose was excreted in the urine over a 7-day period.[20] Due to its long half-life, suramin can be detected in urine for extended periods, sometimes exceeding 140 days following infusion.[20]
• Key Pharmacokinetic Parameters:
• Half-life (t1/2​): Suramin has a very long elimination half-life, generally reported to be between 36 to 60 days.[1] A Phase I study in healthy Chinese volunteers found an average plasma half-life of 48 days (range 28-105 days), which appeared to be dose-independent within the tested range.[20] However, a study involving a single low dose (20 mg/kg) in children with ASD reported a notably shorter terminal half-life of approximately 14.7 ± 0.7 days.[56] This discrepancy could be attributed to several factors, including dose-dependent kinetics (where lower doses might not saturate elimination or distribution mechanisms to the same extent as higher or multiple doses), age-related physiological differences in drug handling (e.g., renal function relative to body size, differences in protein binding), or variations in study design and analytical methods. Such differences are critical when considering dosing regimens, particularly in pediatric populations or for new indications requiring different exposure levels. The extremely long half-life observed in most adult studies implies a significant risk of drug accumulation with repeated dosing, which is directly linked to its toxicity profile, especially nephrotoxicity. This necessitates carefully planned, spaced-out dosing regimens and vigilant patient monitoring.
• Clearance: Specific clearance values are not consistently provided across the available information, but the long half-life and high protein binding suggest that systemic clearance is low.
• Cmax​ and AUC: Following single IV doses, the maximum plasma concentration (Cmax​) and the area under the plasma concentration-time curve (AUC) of suramin have been shown to increase in a dose-proportional manner within the tested ranges.[20]

Table 2: Summary of Pharmacokinetic Parameters of Suramin

Parameter	Value / Description	Snippet(s) Reference(s)
Route of Administration	Parenteral (typically Intravenous)	3
Oral Bioavailability	Poor / Negligible	1
Protein Binding	~99-99.7% (primarily to albumin)	3
Volume of Distribution (Vd)	31-46 Liters	33
CNS Penetration	Poor at standard therapeutic doses	2
Metabolism Pathway	Little to no metabolism	1
Metabolites	None significant	1
Route of Excretion	Primarily renal (unchanged drug)	25
Elimination Half-life (t1/2​)	Approx. 36-60 days (adults); Average 48 days (range 28-105 days) in one adult study; ~14.7 days in one pediatric study (single low dose)	1
Clearance	Low (inferred from long t1/2​ and high protein binding)	General PK principles
Cmax​/AUC Proportionality	Dose-proportional increase with single IV doses	20

5. Therapeutic Applications and Clinical Evidence

Suramin's therapeutic applications span over a century, with well-established roles in treating certain parasitic diseases and a history of investigation for a wide range of other conditions, including cancer, viral infections, and neurodevelopmental disorders.

5.1. Approved Indications

5.1.1. Human African Trypanosomiasis (HAT)

Suramin is a cornerstone in the treatment of early-stage (hemolymphatic stage, without CNS involvement) Human African Trypanosomiasis.[1] It is particularly indicated for infections caused by Trypanosoma brucei rhodesiense (East African sleeping sickness) and can be used as an alternative agent for early-stage Trypanosoma brucei gambiense (West African sleeping sickness).[4] For early-stage T. b. rhodesiense, suramin is often considered a first-line treatment, whereas for early-stage T. b. gambiense, pentamidine has traditionally been the first-line option, although fexinidazole is now also recommended for both forms depending on specific criteria.[4]

The typical adult dosage regimen involves an initial intravenous test dose (e.g., 100 mg or 4-5 mg/kg) to assess for hypersensitivity reactions. This is followed by a series of intravenous injections of 20 mg/kg (maximum 1g per injection) administered on days 1, 3, 7, 14, and 21, or a similar weekly schedule for 5-6 weeks.[2] Pediatric dosages are adjusted accordingly.[32] Due to its poor penetration into the central nervous system, suramin is not effective for late-stage (meningoencephalitic) HAT.[2] However, it is sometimes used in pregnant women with late-stage disease as a holding measure until melarsoprol, which is contraindicated during pregnancy, can be administered after delivery.[6]

5.1.2. Onchocerciasis (River Blindness)

Historically, suramin was used, often in conjunction with diethylcarbamazine, for the treatment of onchocerciasis due to its ability to kill adult Onchocerca volvulus worms (macrofilaricidal effect).[1] WHO documents from 1969 indicated that an optimal adult dosage regimen consisted of 5 or 6 weekly doses of 1.0g.[49] However, due to its significant toxicity profile compared to safer and more easily administered alternatives like ivermectin, the current use of suramin for onchocerciasis is very limited, and some sources no longer recommend it for this indication.[6]

5.2. Investigational Uses and Clinical Trials

5.2.1. Oncology

Suramin has demonstrated potent antineoplastic properties in preclinical studies and has been investigated in various human cancers.[1]

• Glioblastoma Multiforme (GBM): A Phase II study conducted by the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium evaluated suramin in combination with standard cranial radiotherapy for newly diagnosed GBM. While the combination was found to be tolerable, it did not result in a significant improvement in overall survival (median survival was 11.6 months) compared to historical controls.[28] The pharmacokinetics of suramin appeared to be unaffected by concomitant anticonvulsant medications in these patients.[54]
• Prostate Cancer: Suramin showed modest activity in patients with metastatic, hormone-refractory prostate cancer.[16] Studies explored intermittent dosing schedules aimed at maintaining plasma suramin concentrations between 100 and 300 µg/mL, which reportedly reduced toxicities without compromising antineoplastic activity.[33]
• Breast Cancer: In vitro studies demonstrated anti-proliferative effects of suramin on both tamoxifen-sensitive and tamoxifen-resistant breast cancer cell lines. In ZR-75-1 cells and their variants, sensitivity to suramin was associated with increased expression of IGF-I receptors and decreased expression of EGFR. However, this relationship was not universally observed across all tested cell lines. An unexpected finding was the growth stimulation observed in tamoxifen-resistant cell lines when treated with suramin in the presence of tamoxifen, the mechanism for which remains unclear.[53]
• Non-Small Cell Lung Cancer (NSCLC): A Phase II trial (NCT01038752) investigating suramin for NSCLC was discontinued.[7] Earlier, Ohio State University was involved in early clinical development of suramin in combination with docetaxel or gemcitabine for advanced NSCLC.[16]
• Adrenocortical Carcinoma: The National Cancer Institute (NCI) has conducted Phase II studies of suramin for adrenocortical carcinoma.[16]
• Other Cancers: Suramin has also been investigated for bladder cancer, lymphomas, and sarcomas.[7] Despite initial promise, the development of suramin for many cancer indications has been discontinued, largely due to its significant toxicity profile and the emergence of more targeted and less toxic therapies.[7] The challenge of achieving a favorable therapeutic window, where anticancer efficacy is achieved without unacceptable side effects, has been a major hurdle.

5.2.2. Autism Spectrum Disorder (ASD)

The investigation of suramin for ASD is a more recent development, primarily driven by its antipurinergic activity and the Cell Danger Response (CDR) hypothesis. This hypothesis posits that chronic, abnormal purinergic signaling contributes to the core symptoms of ASD, and suramin, by inhibiting these signals, might offer therapeutic benefits.[9]

• SAT-1 Trial (NCT02508259): A small, randomized, double-blind, placebo-controlled Phase I/II trial conducted at the University of California, San Diego (UCSD) provided initial human data. Ten male children with ASD received a single low dose of intravenous suramin (20 mg/kg) or saline. The study reported statistically significant improvements in core symptoms of autism, as measured by the Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2) comparison scores, in the suramin-treated group compared to placebo. The treatment was generally well-tolerated, with the most common adverse event being a transient, asymptomatic rash. The terminal half-life of suramin in this pediatric population after a single low dose was reported to be approximately 14.7 days.[8]
• PaxMedica Development (PAX-101 and PAX-102): PaxMedica is actively developing suramin formulations for ASD.
• PAX-101 (IV Suramin): A Phase 2 dose-ranging clinical trial involving 52 children with moderate to severe ASD was conducted in South Africa. This study evaluated two doses of PAX-101 (10 mg/kg and 20 mg/kg) or placebo administered as infusions every 4 weeks for three doses. The results indicated sustained improvements over placebo in several efficacy measures, including the Aberrant Behavior Checklist (ABC) Core score and the Clinical Global Impression of Improvement (CGI-I) scale, particularly with the 10 mg/kg dose. The drug was reported to be generally safe and tolerable in this study population.[9] PaxMedica is advancing PAX-101 for ASD treatment.[12]
• PAX-102 (Intranasal Suramin): PaxMedica is also developing a proprietary intranasal formulation of suramin, PAX-102, which is being evaluated for ASD and other neurodevelopmental conditions.[12] A significant milestone was the granting of a patent in China in January 2025 for this intranasal formulation for treating neurological disorders, including autism. The patent claims cover the novel intranasal delivery method as an alternative to traditional infusion dosing.[13] The rationale for intranasal delivery includes potentially improved CNS delivery, circumvention of the blood-brain barrier to some extent, reduced systemic side effects, and enhanced patient compliance.

5.2.3. Viral Infections

Suramin's broad-spectrum antiviral activity has led to its investigation against various viral pathogens.

• SARS-CoV-2 (COVID-19): In vitro studies have demonstrated that suramin inhibits the replication of SARS-CoV-2 in Vero E6 cells with an EC50 of approximately 20 µM. Its mechanism appears to involve interference with early steps of the viral replication cycle, such as binding and/or entry, and direct inhibition of the viral RNA-dependent RNA polymerase (RdRp).[10] These findings have positioned suramin as a candidate for further preclinical assessment for COVID-19.[11] A March 2025 review on COVID-19 antivirals, while not specifically mentioning suramin, did discuss polymerase inhibitors as a general class of interest.[65]
• Hand Foot Mouth Disease (HFMD): Based on preclinical antiviral effects against Enterovirus 71 (EV71), a major cause of HFMD, injected suramin sodium has been developed by Hainan Honz Pharmaceutical Co. Ltd in China for the treatment of HFMD.[33] A Phase I clinical trial (NCT03804749) in healthy Chinese volunteers was conducted to provide pharmacokinetic and safety data to support this development.[35] Follow-up studies investigating long-term sequelae of HFMD are reportedly ongoing.[66]
• Other Viruses: Suramin has shown in vitro activity against a range of other viruses, including HIV (by inhibiting reverse transcriptase), Hepatitis C virus, Herpes Simplex virus, Zika virus, Dengue virus, Chikungunya virus, and Ebola virus.[2]

5.2.4. Other Potential Applications

• Snakebite: Due to its ability to inhibit enzymes like thrombin and phospholipase A2, which are common components of snake venoms, suramin has been explored as a potential snakebite antivenom.[2]
• Antibacterial: Suramin's capacity to inhibit bacterial RecA protein and the SOS DNA damage response pathway presents a novel antibacterial strategy. This could be particularly relevant for Mycobacterium tuberculosis and for combating antibiotic resistance.[29]

Table 3: Overview of Approved and Major Investigational Uses of Suramin

Indication	Primary Mechanism Focus for Indication	Key Clinical Trial(s)/Evidence (Phase, Key Finding)	Current Status	Snippet(s) Reference(s)
Human African Trypanosomiasis (T.b. rhodesiense, early stage)	Inhibition of trypanosomal enzymes (e.g., NADH oxidation), ISG75-mediated uptake, disruption of cytokinesis	Long historical use; WHO treatment guidelines	Approved; First-line	4
Human African Trypanosomiasis (T.b. gambiense, early stage)	As above	WHO treatment guidelines	Approved; Alternative agent	4
Onchocerciasis	Macrofilaricidal (adult worm killing), partial microfilaricidal	Historical use; Older dosage studies	Approved, but use very limited due to toxicity	1
Glioblastoma Multiforme	Antagonism of growth factors (PDGF, bFGF, VEGF), anti-angiogenesis	NABTT Phase II (with RT): Tolerable, no significant survival benefit	Investigational; Largely discontinued	28
Prostate Cancer (metastatic, hormone-refractory)	Antagonism of growth factors	Phase II/III trials: Modest activity	Investigational; Largely discontinued	7
Autism Spectrum Disorder (ASD)	Antipurinergic activity (P2 receptor antagonism), modulation of Cell Danger Response	SAT-1 (Phase I/II): Single low dose improved core symptoms. PaxMedica PAX-101 Phase 2: 10mg/kg IV showed improvements in ABC Core, CGI-I.	Investigational (Phase 2/3 for IV; Early development for intranasal)	8
SARS-CoV-2 (COVID-19)	Inhibition of viral entry/RdRp	In vitro studies: EC50 ~20 µM	Preclinical/Investigational	10
Hand Foot Mouth Disease (EV71)	Antiviral (mechanism likely inhibition of viral replication)	Phase I (PK/safety in healthy volunteers, NCT03804749) by Hainan Honz	Investigational (China)	33

6. Safety, Tolerability, and Risk Management

The clinical utility of suramin is significantly constrained by its substantial and varied adverse effect profile. While effective for certain conditions, its administration requires careful medical supervision and risk assessment.

6.1. Adverse Effect Profile

Suramin is associated with a considerable number of side effects, ranging from mild and transient to severe and life-threatening.[25]

• Common Adverse Effects: Frequently reported side effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. Patients may also experience a metallic taste, headache, general malaise, fatigue, and irritability. Dermatological reactions like skin rash, itching, and tingling or crawling sensations (paresthesias) of the skin, particularly on the palms and soles, are common. Joint pain (arthralgia) and loss of appetite can also occur. A characteristic, though non-harmful, effect is cloudy urine, which indicates the renal presence of the drug.[25]
• Less Common Adverse Effects: These may include changes in or loss of vision, extreme tiredness or weakness, increased sensitivity of the eyes to light (photosensitivity), painful and tender lymph glands (in the neck, armpits, or groin), swelling around the eyes, and ulcers or sores in the mouth.[57]
• Rare/Serious Adverse Effects:
• Hypersensitivity Reactions: Suramin can induce severe hypersensitivity reactions, including anaphylactic shock, which can manifest as difficulty breathing, decreased blood pressure, and loss of consciousness. This risk necessitates the administration of a test dose prior to initiating full therapy.[4]
• Nephrotoxicity: Kidney damage is a significant concern. Proteinuria (excessive protein in the urine) is a common finding and can progress to more severe renal impairment or even kidney failure, particularly in patients with pre-existing kidney disease or with prolonged/high-dose therapy.[6] Regular monitoring of renal function is crucial.
• Neurotoxicity: Neurological side effects can include peripheral neuropathy (manifesting as numbness, weakness, or paresthesias in the extremities), optic atrophy (which can lead to vision loss), convulsions, and dizziness. It has been suggested that plasma suramin levels exceeding 350 µg/mL may increase the risk of neurotoxicity and coagulopathy.[25]
• Hematologic Toxicity: Suramin can affect blood cell counts, leading to conditions such as pancytopenia (a deficiency of all types of blood cells), anemia, neutropenia (low neutrophils), and thrombocytopenia (low platelets). These can result in unusual bleeding, bruising, increased susceptibility to infections, and severe fatigue.[25]
• Cardiovascular Effects: Hypotension (low blood pressure) and tachycardia (rapid heart rate) have been reported.[24]
• Hepatic Toxicity: Potential for liver damage, indicated by symptoms like jaundice (yellowing of the skin and eyes) or abnormal liver function tests, exists.[57]
• Other Serious Effects: Severe skin reactions like exfoliative dermatitis, high fever (with or without chills), sore throat, and swelling or tenderness in the upper abdominal area can occur.[24]

6.2. Specific Organ Toxicities

• Nephrotoxicity: This is one of the most common and dose-limiting toxicities of suramin. The drug is concentrated and excreted by the kidneys. While the exact mechanism of renal damage is not fully elucidated, it often manifests initially as proteinuria. Continued exposure can lead to progressive renal tubular damage and impaired glomerular filtration. Monitoring involves regular urinalysis for protein and assessment of serum creatinine and blood urea nitrogen (BUN).
• Neurotoxicity: Peripheral neuropathy is a recognized complication, potentially related to the drug's long half-life and accumulation. Optic atrophy is a severe but rarer neurological side effect. The risk appears to be dose and concentration-dependent.
• Hematologic Toxicity: Bone marrow suppression leading to cytopenias can occur, requiring monitoring of complete blood counts.

6.3. Contraindications, Warnings, and Precautions

• Contraindications:
• Known hypersensitivity to suramin or any of its components is an absolute contraindication.[58]
• Severe pre-existing renal or hepatic disease is generally considered a contraindication or requires extreme caution and dose modification, as these conditions can impair drug elimination and exacerbate toxicity.[6] The advice to avoid suramin in patients with impaired kidney or liver function is directly linked to its primary route of elimination (renal) and its potential for direct organ toxicity. Impaired renal function would reduce clearance, prolong its already long half-life, and increase systemic exposure, thereby heightening the risk and severity of toxicities, particularly nephrotoxicity itself.
• Warnings:
• Hypersensitivity: The risk of severe, immediate hypersensitivity reactions, including anaphylactic shock, is significant. A small test dose is typically administered intravenously before the first full therapeutic dose to assess for idiosyncratic reactions.[4] This practice underscores the drug's potential to elicit severe, rapid-onset adverse events.
• Nephrotoxicity: Patients must be closely monitored for signs of kidney damage throughout treatment and even after discontinuation, given the drug's long persistence in the body.[6]
• Co-infection with Onchocerca volvulus: In patients with HAT who are also co-infected with O. volvulus (common in some T.b. gambiense endemic areas), treatment with suramin for HAT can provoke severe reactions, likely related to the killing of microfilariae. Screening for onchocerciasis and careful consideration of alternative therapies may be necessary in such cases.[4]
• Pregnancy: Suramin is known to be toxic and animal studies have shown evidence of congenital malformations.[68] However, untreated HAT is fatal. Therefore, in pregnant women with early-stage T.b. rhodesiense HAT, treatment with suramin may be considered if the potential benefit justifies the potential risk to the fetus. It is also sometimes used as a temporizing measure in late-stage HAT during pregnancy until melarsoprol can be safely administered after delivery.[6] Pregnant women are advised to avoid travel to trypanosomiasis-endemic regions.
• Breastfeeding: It is not known whether suramin is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, caution should be exercised, and the decision to use suramin should take into account the importance of the drug to the mother.[25]
• Precautions:
• Suramin should be administered exclusively in a hospital setting or under the close supervision of a physician experienced in its use, allowing for immediate management of potential acute reactions.[57]
• Elderly patients may exhibit increased sensitivity to the effects of suramin and may be at higher risk for side effects.[57]
• Adequate hydration should be maintained throughout the treatment course to support renal function and minimize the risk of nephrotoxicity.[6]
• Regular and comprehensive monitoring is essential. This includes frequent assessment of renal function (urinalysis for proteinuria, serum creatinine, BUN), liver function tests, complete blood counts, and neurological status. Monitoring should continue even after the completion of treatment due to the drug's long elimination half-life.[6]

6.4. Drug Interactions

Information regarding specific drug interactions with suramin is somewhat limited in the provided sources. One source mentions "no known severe, serious, moderate or mild interactions with other drugs" 68, but this statement should be interpreted cautiously, as suramin is a highly protein-bound drug with significant systemic effects, making pharmacokinetic and pharmacodynamic interactions plausible. The pharmacology of suramin appeared unaffected by anticonvulsants in patients with glioblastoma multiforme.54

DrugBank lists potential interactions, including an increased risk of methemoglobinemia when suramin is combined with certain local anesthetics (e.g., benzocaine, lidocaine) and an increased risk of thrombosis when combined with erythropoietin or related agents.3 Given its high degree of protein binding (approximately 99.7%), suramin has the potential to displace other protein-bound drugs from their binding sites, or be displaced itself, potentially altering their free concentrations and pharmacological effects. Clinicians should exercise caution and carefully review all concomitant medications when prescribing suramin.

Table 4: Clinically Significant Adverse Effects and Toxicities of Suramin

System/Organ Class	Specific Adverse Effect	Typical Severity/Frequency	Key Monitoring/Management Notes	Snippet(s) Reference(s)
Immune System	Hypersensitivity reactions, Anaphylactic shock	Rare/Serious	Administer test dose; monitor closely during/after infusion; have resuscitation equipment ready.	6
Renal and Urinary	Proteinuria, Nephrotoxicity, Renal impairment/failure	Common (proteinuria) to Serious	Regular urinalysis, serum creatinine, BUN; ensure hydration; dose adjustment or discontinuation if severe.	6
Nervous System	Peripheral neuropathy, Paresthesias, Headache, Dizziness, Optic atrophy, Convulsions	Common (paresthesia, headache) to Rare/Serious (optic atrophy, convulsions)	Neurological examinations; monitor for symptoms; consider plasma level monitoring if available (>350 µg/mL associated with increased risk).	25
Gastrointestinal	Nausea, Vomiting, Diarrhea, Abdominal pain, Stomatitis, Metallic taste	Common	Symptomatic treatment; monitor hydration and nutritional status.	25
Hematologic	Pancytopenia, Anemia, Neutropenia, Thrombocytopenia	Less common to Rare/Serious	Regular complete blood counts.	25
Dermatologic	Rash, Itching, Exfoliative dermatitis, Paresthesias of skin	Common	Symptomatic treatment; monitor for severe reactions.	25
General/Systemic	Fever, Fatigue, Malaise, Weight loss, Painful/tender glands	Common to Less common	Monitor vital signs and general well-being.	25
Cardiovascular	Hypotension, Tachycardia	Rare/Serious	Monitor blood pressure and heart rate.	25
Hepatic	Liver damage, Jaundice	Rare/Serious	Monitor liver function tests.	57
Ocular	Changes in vision, Loss of vision, Photosensitivity, Watery eyes	Less common to Rare/Serious	Ophthalmologic examination if symptoms occur.	25

7. Regulatory Status, Manufacturing, and Availability

7.1. Global Regulatory Approvals

Suramin's regulatory status varies globally, reflecting its long history and specific regional health needs.

• Food and Drug Administration (FDA), USA: Suramin is an FDA-approved drug for the treatment of African Sleeping Sickness (Human African Trypanosomiasis) and River Blindness (Onchocerciasis).[5] More recently, PaxMedica, Inc. received Orphan Drug Designation from the FDA for suramin for the "Treatment of human African trypanosomiasis" on January 25, 2021. However, this designation does not yet constitute FDA approval for PaxMedica's specific product for this orphan indication.[69]
• European Medicines Agency (EMA) and Europe: Specific EMA-wide marketing authorization for "Suramin" or "Germanin" is not clearly detailed in the provided information. While fexinidazole has received a positive opinion from the EMA for HAT [61], the status of suramin itself under its traditional trade names in the EU is less clear from these documents. Historically, Bayer (Germany) has been the primary manufacturer.[18] One source from 2023 indicates that sleeping sickness caused by T.b. rhodesiense is the only human disease for which treatment with suramin is "currently approved" (in a global or historical context).[18] Availability in European countries like France, Belgium, UK, Germany, or Portugal for routine clinical use would likely be through specialized import mechanisms, compassionate use programs, or via tropical medicine institutes, rather than broad marketing authorization.
• World Health Organization (WHO): Suramin sodium is included on the WHO Model List of Essential Medicines. Its listed indications include the treatment of 1st stage African Trypanosomiasis and Filariasis.[3] The WHO plays a crucial role in providing suramin free of charge in regions where HAT is endemic.[25]

7.2. Manufacturing and Supply Chain

The manufacturing and supply of suramin have faced challenges over the years.

• Original Manufacturer: Bayer AG in Germany is the original manufacturer of suramin, marketed under the brand name Germanin®.[1]
• Historical Supply Issues: There have been concerns about the sustainability of suramin production. Bayer reportedly threatened to cease production on several occasions, citing the lack of alternatives and economic or ecological constraints (e.g., issues with raw materials for related drugs like melarsoprol).[24] Organizations like Médecins Sans Frontières (MSF) and the WHO have historically intervened to help secure the production and availability of essential HAT drugs, including suramin.[24] This recurring theme of supply insecurity for a WHO Essential Medicine highlights a critical vulnerability in global public health, particularly for diseases predominantly affecting impoverished populations. The reliance on a limited number of manufacturers for such "older" drugs, which may have limited commercial markets, makes their supply susceptible to disruptions.
• Current Suppliers and Developers:
• Bayer (Germanin®): Continues to be a source, with Germanin® supplied to the U.S. Centers for Disease Control and Prevention (CDC) by the WHO.[31]
• PaxMedica, Inc.: This biopharmaceutical company is actively involved in developing suramin formulations.
• PAX-101 (IV suramin): PaxMedica has completed pivotal registration/validation batches of PAX-101 as of April 2024, in preparation for a potential New Drug Application (NDA) submission to the FDA for the treatment of HAT caused by T.b. rhodesiense.[36] The company aims to provide an additional, reliable global source of suramin.[13] In August 2024, PaxMedica reported the first patient treated with PAX-101 for HAT under an emergency access program.[36] The company's strategy to seek FDA approval for HAT, an orphan indication, may be partly motivated by the potential to obtain a Priority Review Voucher (PRV).[12] A PRV can be sold to other pharmaceutical companies, providing a significant financial incentive to develop drugs for neglected diseases that might otherwise lack commercial viability. This is a recognized mechanism to stimulate research and development in areas of high unmet medical need but low profitability.
• PAX-102 (intranasal suramin): Also under development by PaxMedica, primarily for ASD.[12]
• Hainan Honz Pharmaceutical Co. Ltd: This Chinese company has developed an injected suramin sodium formulation for the treatment of Hand Foot Mouth Disease (HFMD) associated with Enterovirus 71 (EV71) in China.[33]

7.3. Availability in Specific Regions/Programs

• United States: Suramin can be acquired from the CDC for the treatment of HAT, typically under an Investigational New Drug (IND) protocol, as its commercial availability for this indication is limited.[4]
• Europe: While Bayer is based in Germany, routine availability of suramin (Germanin®) for clinical use in many European countries (e.g., France, Belgium, UK, Portugal) is not widespread and often relies on special access programs or importation managed by tropical medicine institutes or national health authorities for treating imported cases of HAT.[24]
• Africa: In HAT-endemic regions, suramin is often provided free of charge by the WHO as part of control programs.[25] However, as evidenced by an emergency request from Malawi to PaxMedica in April 2024 due to dwindling supplies, availability can still be a critical issue, underscoring the fragility of the supply chain for this essential medicine.[73]

8. Current Research and Future Perspectives

Despite its age, suramin continues to be a subject of active research, focusing on novel formulations, the development of analogues with improved profiles, and the exploration of new therapeutic applications based on emerging mechanistic insights.

8.1. Development of Novel Formulations

A significant area of current research involves developing novel formulations of suramin to overcome its pharmacokinetic limitations (e.g., poor membrane permeability, lack of oral bioavailability, poor CNS penetration) and to potentially reduce systemic toxicity or improve patient compliance.

• Intranasal Suramin (PaxMedica's PAX-102):
• Rationale: The development of an intranasal formulation of suramin, PAX-102, by PaxMedica is primarily aimed at treating neurological disorders such as Autism Spectrum Disorder (ASD).[12] Intranasal delivery offers a potential route for direct nose-to-brain (N2B) transport, which could bypass the blood-brain barrier (BBB) to some extent, thereby achieving therapeutic concentrations in the CNS with lower systemic exposure. This approach could reduce systemic side effects commonly associated with intravenous suramin and improve patient compliance, particularly in pediatric populations or for chronic conditions requiring long-term treatment. The ability of intranasal suramin to effectively reach the CNS would be a significant advancement, given that poor BBB penetration is a major hurdle for systemically administered suramin in treating CNS disorders.
• Mechanism of Nose-to-Brain Delivery: N2B delivery can occur via the olfactory and trigeminal neural pathways, allowing substances to travel from the nasal cavity directly to the brain.[75] Nanoformulations are often explored to enhance this transport and protect the drug from degradation.[75] However, challenges such as rapid mucociliary clearance from the nasal cavity and enzymatic degradation within the nasal mucosa need to be addressed to ensure efficient drug delivery.[75]
• Development Status: PaxMedica has filed patent applications for its intranasal suramin compositions and methods of use. Notably, patent application WO2022087174A1 describes these intranasal formulations for treating a range of nervous system disorders, including ASD.[39] In January 2025, PaxMedica announced that it had received its first patent allowance for this technology in China (Chinese Invention Patent Application No: 2020800553323).[13] The company has stated that PAX-102 is currently being evaluated for ASD and other neurodevelopmental conditions.[12]
• Preclinical Data: Specific preclinical data detailing the CNS pharmacokinetics, efficacy in animal models of ASD, or behavioral outcomes for PAX-102 are not extensively detailed in the currently available public domain information.[12] The patent application [39] suggests that antipurinergic agents like suramin can be administered intranasally for these disorders based on pharmacokinetic and pharmacodynamic treatment regimens not previously contemplated in scientific literature. Further peer-reviewed publications or conference presentations detailing such preclinical work would be crucial for assessing the viability of this approach.

8.2. Suramin Analogues and Derivatives

Given suramin's potent biological activities alongside its significant toxicity, there has been ongoing interest in developing analogues or derivatives. The primary goals of such efforts are typically to create compounds with an improved therapeutic index—either by enhancing efficacy, reducing toxicity, or both—or to develop molecules with novel applications or better selectivity for specific targets.[14]

• Structure-Activity Relationship (SAR) Studies: Research into suramin analogues has provided valuable insights into its SAR, particularly for its trypanocidal activity. Studies have consistently shown that certain structural features of the suramin molecule are critical for its potent effect against trypanosomes. These include the presence of methyl groups on the intermediate phenyl rings and the specific regiochemistry (pattern of substitution) of the naphthalenetrisulphonic acid groups.[14] Analogues lacking these specific features, for example, those without the methyl groups or with altered positioning of the sulfonic acid groups, have demonstrated significantly lower trypanocidal activity. Interestingly, these structural modifications can also alter the mechanism of action; while suramin inhibits cytokinesis in Trypanosoma brucei, some of these less active analogues were found to inhibit mitosis instead.[14] These findings strongly suggest that any attempts to create suramin analogues for treating trypanosomiasis must carefully consider preserving or effectively mimicking these key pharmacophoric elements to maintain efficacy. Simply aiming to reduce molecular size or overall charge without respecting these specific structural requirements may lead to a substantial loss of antiparasitic activity.
• Novel Scaffolds and Modifications: A 2021 study reported the synthesis of several suramin derivatives that incorporated variations in the aryl sulfonic acid moieties (using mono- or trisulfonic acids of naphthalene) and featured different lengths of the symmetrical urea structures. Some of these derivatives showed promising anti-proliferative activity by inhibiting the binding of Fibroblast Growth Factor 1 (FGF1) to its receptor FGFRD2, and importantly, were suggested to have lower cytotoxicity than the parent suramin molecule.[15] Other synthetic strategies have involved replacing parts of the suramin backbone, for example, by introducing heterocyclic building blocks like nitrothiophene into the symmetrical urea structure.[15]
• Recent Research (2023-2025): A study published in March 2024 (PMID: 38513971) further reinforced the importance of the specific methyl and naphthalenetrisulphonic acid group configurations for suramin's potent trypanocidal action.[14] Other recent research, such as a study on quinobenzothiazine derivatives bearing sulfonic acid groups [77], explores related chemical space for different therapeutic activities (e.g., antioxidant, antihyperlipidemic, anti-glycation). While these are not direct suramin analogues, they reflect the continued interest in polysulfonated aromatic compounds for biological applications.

8.3. Emerging Mechanistic Insights and Therapeutic Targets

Ongoing research continues to uncover new mechanistic details and potential therapeutic targets for suramin, underscoring its polypharmacological nature.

• Antiviral Research: There is sustained interest in suramin's broad-spectrum antiviral capabilities, particularly in the context of emerging viral threats. Its mechanisms often involve blocking viral entry into host cells or inhibiting key viral enzymes, such as the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2.[2] The COVID-19 pandemic notably spurred renewed investigation into suramin as a potential antiviral agent.[11]
• Antibacterial Research (RecA Inhibition): Suramin's ability to potently inhibit bacterial RecA proteins and the associated SOS DNA damage response pathway presents a novel antibacterial strategy.[29] RecA is crucial for DNA repair and the development of antibiotic resistance in many pathogenic bacteria, including Mycobacterium tuberculosis. By targeting RecA, suramin could potentially be used to combat drug-resistant infections or to enhance the efficacy of existing antibiotics. While much of the foundational research in the provided snippets dates to around 2014, this remains a compelling and underexplored avenue for suramin.
• Neurodevelopmental and Neurological Disorders (Beyond ASD): The patent secured by PaxMedica for its intranasal suramin formulation (PAX-102) covers a broader range of "cognitive, social, or behavioral disabilities and neurodevelopmental disorders," suggesting potential applications beyond ASD.[13]
• Exploration of Polypharmacology: A deeper understanding of the full spectrum of suramin's molecular targets and how these interactions contribute to its diverse biological effects could unveil further therapeutic opportunities.[2] Identifying which targets are most relevant for specific diseases could lead to more rational drug development or patient stratification strategies.

Table 5: Key Companies and Their Suramin-Based Development Programs

Company Name	Product Name(s)	Key Indication(s) Being Pursued	Current Development Stage	Key Recent Milestone/Update	Snippet(s) Reference(s)
Bayer AG	Germanin®	Human African Trypanosomiasis (T.b. rhodesiense)	Marketed (historical manufacturer)	Supplies Germanin® to WHO/CDC for HAT treatment.	18
PaxMedica, Inc.	PAX-101 (IV Suramin)	Human African Trypanosomiasis (T.b. rhodesiense); Autism Spectrum Disorder (ASD)	HAT: Pre-NDA (registration batches complete); ASD: Phase 2 completed, planning further studies	HAT: First patient treated under emergency access (Aug 2024); Registration batches completed (Apr 2024); ASD: Phase 2 results published (Nov 2023).	9
	PAX-102 (Intranasal Suramin)	Autism Spectrum Disorder (ASD); Other neurological/neurodevelopmental disorders	Preclinical/Early Clinical Evaluation; Patent Stage	Patent allowance in China for intranasal formulation for neurological disorders including ASD (Jan 2025).	12
Hainan Honz Pharmaceutical Co. Ltd	Injected Suramin Sodium	Hand Foot Mouth Disease (HFMD) associated with EV71	Phase I completed (healthy volunteers, China); Further clinical development for HFMD implied.	Phase I PK/safety data published (2023) to support HFMD development in children.	33

9. Conclusion and Expert Insights

Suramin occupies a unique and enduring position in the history of pharmacology. Developed over a century ago, its initial success against devastating parasitic diseases like Human African Trypanosomiasis has paved the way for continued exploration of its broad biological activities. This polyanionic naphthylurea derivative is now recognized not only for its established antiparasitic roles but also for its investigational potential in complex conditions such as various cancers, Autism Spectrum Disorder, and a range of viral infections. This remarkable versatility stems from its ability to interact with a multitude of molecular targets, a characteristic often termed polypharmacology.

However, the primary challenge that has consistently shadowed suramin's therapeutic journey is balancing its demonstrable efficacy against a significant and often dose-limiting toxicity profile. Its pharmacokinetic complexities, including poor oral bioavailability, the necessity for parenteral administration, and an exceptionally long elimination half-life leading to potential accumulation, further complicate its clinical use and risk management.

Modern research endeavors are actively seeking to address these longstanding challenges and to unlock new therapeutic applications for suramin. These efforts are multifaceted:

• Novel Formulations: The development of new delivery systems, most notably intranasal suramin (e.g., PaxMedica's PAX-102), represents a significant attempt to improve drug targeting, particularly to the central nervous system for neurological disorders like ASD. Such approaches aim to enhance efficacy, reduce systemic exposure and associated side effects, and improve patient compliance. The fact that a drug developed long before the era of targeted CNS delivery is now being re-evaluated with modern formulation strategies like N2B delivery highlights how innovation can breathe new life into older compounds.
• Analogue Development: The synthesis and evaluation of suramin analogues continue, with the goal of identifying derivatives that retain or enhance therapeutic activity while exhibiting a more favorable safety profile. Structure-activity and structure-toxicity relationship studies are crucial in this regard, guiding the design of molecules that might be more selective or less prone to off-target effects. The consistent finding that specific structural motifs within the suramin molecule are critical for its potent trypanocidal activity, for instance, provides vital clues for rational analogue design for that indication.
• Deeper Mechanistic Understanding: Ongoing research into suramin's diverse mechanisms of action is gradually moving beyond a general "polypharmacology" label towards a more precise understanding of which molecular targets are most relevant for each specific disease state. This could enable more targeted therapeutic applications and potentially biomarker-guided patient selection. The fact that a drug developed empirically continues to yield new mechanistic insights (e.g., its role as a RecA inhibitor or its complex effects on purinergic signaling in the context of the Cell Danger Response hypothesis for ASD) underscores the value of continued investigation even for well-established medicines.

Key Challenges Ahead:

• Mitigating Toxicity: Reducing the inherent toxicities (nephrotoxicity, neurotoxicity, hypersensitivity) remains paramount.
• Improving Pharmacokinetics: Overcoming poor oral bioavailability and, for certain indications like late-stage HAT or primary CNS disorders, inadequate CNS penetration are major hurdles.
• Ensuring Sustainable Supply: Maintaining a consistent and affordable supply of suramin, particularly for neglected tropical diseases where commercial incentives are low, is a persistent global health challenge.
• Full Mechanistic Elucidation: A complete understanding of its complex interactions is still evolving and is necessary for truly rational drug development and application.

Opportunities for the Future:

• Novel Delivery Systems: Success with formulations like intranasal suramin could revolutionize its application in CNS disorders.
• Targeted Analogues: The development of less toxic, more selective suramin analogues holds promise.
• Antimicrobial Potential: Its broad-spectrum antiviral and novel antibacterial (RecA inhibition) properties could be highly valuable in an era of increasing antimicrobial resistance.
• Personalized Medicine: Biomarker-driven approaches might identify patient populations most likely to benefit from suramin therapy in indications like ASD or specific cancers.

Recommendations for Future Research:

• Continued rigorous investigation into structure-toxicity relationships to guide the design of safer suramin analogues.
• Well-designed, adequately powered clinical trials for new formulations and emerging indications, incorporating robust safety monitoring and detailed pharmacokinetic/pharmacodynamic assessments.
• Further basic research to pinpoint the specific molecular targets and pathways most critical for suramin's efficacy in each distinct therapeutic area.
• Exploration of suramin in combination therapies, where it might act synergistically with other agents or serve as a sensitizer to enhance their effects at lower, less toxic doses.

In final consideration, suramin remains a pharmacologically rich and fascinating molecule. Its "crude drug" characteristics, including its broad activity and associated toxicities, certainly present significant challenges. However, its proven efficacy in critical areas like HAT and its tantalizing potential in a range of other difficult-to-treat conditions justify continued, albeit cautious and highly strategic, research and development. The parallel development tracks by different companies for distinct indications (e.g., PaxMedica for ASD/HAT, Hainan Honz for HFMD, and historical NCI trials for cancer) using the same core molecule reflect both suramin's versatility and the somewhat fragmented nature of pharmaceutical development for older compounds. While this can lead to some duplication of basic safety and pharmacokinetic work, it also fosters a diverse exploration of its therapeutic potential. The focus for the future must be on leveraging innovative pharmaceutical sciences and a deeper biological understanding to harness suramin's benefits while minimizing its inherent risks, ensuring that this century-old drug can continue to contribute to medicine in the 21st century.

Works cited

1. Suramin | C51H40N6O23S6 | CID 5361 - PubChem, accessed May 14, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/5361
2. 100 Years of Suramin - PMC - PubMed Central, accessed May 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7038244/
3. Suramin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed May 14, 2025, https://go.drugbank.com/drugs/DB04786
4. African Trypanosomiasis - Infectious Diseases - Merck Manual Professional Edition, accessed May 14, 2025, https://www.merckmanuals.com/professional/infectious-diseases/extraintestinal-protozoa/african-trypanosomiasis
5. Suramin Sodium | C51H34N6Na6O23S6 | CID 8514 - PubChem, accessed May 14, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Suramin_hexasodium
6. SURAMIN injectable - MSF Medical Guidelines, accessed May 14, 2025, https://medicalguidelines.msf.org/en/viewport/EssDr/english/suramin-injectable-16683160.html
7. Suramin sodium - Bayer - AdisInsight - Springer, accessed May 14, 2025, https://adisinsight.springer.com/drugs/800004055
8. Suramin Completed Phase 1 / 2 Trials for Autism Spectrum Disorder Treatment - DrugBank, accessed May 14, 2025, https://go.drugbank.com/drugs/DB04786/clinical_trials?conditions=DBCOND0006160&phase=1%2C2&purpose=treatment&status=completed
9. PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD) - PR Newswire, accessed May 14, 2025, https://www.prnewswire.com/news-releases/paxmedica-announces-positive-results-from-phase-2-trial-of-pax-101-iv-suramin-in-children-with-autism-spectrum-disorder-asd-301224425.html
10. Suramin | PTPases Inhibitor - MedchemExpress.com, accessed May 14, 2025, https://www.medchemexpress.com/Suramin.html
11. Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle, accessed May 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7526844/
12. Industry Spotlight: Paxmedica - The BRAIN Foundation, accessed May 14, 2025, https://brainfoundation.org/therapeutics-enterprise-ventures/paxmedica/
13. PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions - BioSpace, accessed May 14, 2025, https://www.biospace.com/press-releases/paxmedica-announces-first-patent-allowance-for-suramin-intranasal-formulation-in-the-treatment-of-autism-spectrum-disorder-and-other-conditions
14. Suramin: Effectiveness of analogues reveals structural features that are important for the potent trypanocidal activity of the drug - PubMed, accessed May 14, 2025, https://pubmed.ncbi.nlm.nih.gov/38513971/
15. Synthesis of Novel Suramin Analogs With Anti-Proliferative Activity via FGF1 and FGFRD2 Blockade - Frontiers, accessed May 14, 2025, https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2021.764200/full
16. SURAMIN - New Drug Approvals, accessed May 14, 2025, https://newdrugapprovals.org/2014/11/12/suramin/
17. Suramin | Cancer Treatment, Antiparasitic & Neurodegenerative - Britannica, accessed May 14, 2025, https://www.britannica.com/science/suramin
18. 100 years since the publication of the suramin formula - PMC, accessed May 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10700199/
19. Buy Suramin | 145-63-1 - Smolecule, accessed May 14, 2025, https://www.smolecule.com/products/s003035
20. Suramin sodium | DrugBank Online, accessed May 14, 2025, https://go.drugbank.com/salts/DBSALT000540
21. Suramin Hexasodium - Biorbyt, accessed May 14, 2025, https://www.biorbyt.com/suramin-hexasodium-orb320365.html
22. Suramin (sodium salt) (CAS 129-46-4) - Cayman Chemical, accessed May 14, 2025, https://www.caymanchem.com/product/11126
23. suramin | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed May 14, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728
24. Availability and affordability of treatment for Human African Trypanosomiasis - DNDi, accessed May 14, 2025, https://dndi.org/wp-content/uploads/2001/01/etchegorry_mg_tm-ih_2001_957.pdf
25. Suramin - Wikipedia, accessed May 14, 2025, https://en.wikipedia.org/wiki/Suramin
26. Efficacy of the diamidine DB75 and its prodrug DB289, against murine models of human African trypanosomiasis - ResearchGate, accessed May 14, 2025, https://www.researchgate.net/publication/23189207_Efficacy_of_the_diamidine_DB75_and_its_prodrug_DB289_against_murine_models_of_human_African_trypanosomiasis
27. Suramin exposure alters cellular metabolism and mitochondrial ..., accessed May 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7294092/
28. Suramin and radiotherapy in newly diagnosed glioblastoma: Phase ..., accessed May 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1871972/
29. Suramin is a potent and selective inhibitor of Mycobacterium tuberculosis RecA protein and the SOS response: RecA as a potential target for antibacterial drug discovery | Journal of Antimicrobial Chemotherapy | Oxford Academic, accessed May 14, 2025, https://academic.oup.com/jac/article/69/7/1834/2911194
30. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease - PMC - PubMed Central, accessed May 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2441931/
31. Our Formulary | Infectious Diseases Laboratories - CDC, accessed May 14, 2025, https://www.cdc.gov/laboratory/drugservice/formulary.html
32. Clinical Care of Human African Trypanosomiasis - CDC, accessed May 14, 2025, https://www.cdc.gov/sleeping-sickness/hcp/clinical-care/index.html
33. Pharmacokinetics and safety of suramin | DDDT - Dove Medical Press, accessed May 14, 2025, https://www.dovepress.com/phase-i-single-dose-study-to-assess-the-pharmacokinetics-and-safety-of-peer-reviewed-fulltext-article-DDDT
34. Phase I, Single-Dose Study to Assess the Pharmacokinetics and Safety of Suramin in Healthy Chinese Volunteers, accessed May 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10349579/
35. (PDF) Phase I, Single-Dose Study to Assess the Pharmacokinetics and Safety of Suramin in Healthy Chinese Volunteers - ResearchGate, accessed May 14, 2025, https://www.researchgate.net/publication/372300605_Phase_I_Single-Dose_Study_to_Assess_the_Pharmacokinetics_and_Safety_of_Suramin_in_Healthy_Chinese_Volunteers
36. PXMD - PaxMedica, Inc. Latest Stock News & Market Updates, accessed May 14, 2025, https://www.stocktitan.net/overview/PXMD
37. PaxMedica Inc. (OTC: PXMD) - IBN (InvestorBrandNetwork), accessed May 14, 2025, https://www.investorbrandnetwork.com/clients/paxmedica-inc/
38. PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions - Stock Titan, accessed May 14, 2025, https://www.stocktitan.net/news/PXMD/pax-medica-announces-first-patent-allowance-for-suramin-intranasal-ctlqd2hwoo7f.html
39. WO2022087174A1 - Intranasal administration of suramin for treating ..., accessed May 14, 2025, https://patents.google.com/patent/WO2022087174A1/en
40. PaxMedica selected by American Academy of Child and Adolescent Psychiatry (AACAP) to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD) in the Research Pipeline Program, accessed May 14, 2025, https://www.paxmedica.com/news/paxmedica-selected-by-american-academy-of-child-and-adolescent-psychiatry-aacap-to-present-data-from-its-recent-phase-2
41. Suramin for Autism Update: 2023 and Beyond - The BRAIN Foundation, accessed May 14, 2025, https://brainfoundation.org/suramin-for-autism-update-2023/
42. PaxMedica Announces First Patent Allowance for Suramin ..., accessed May 14, 2025, https://www.biospace.com/press-releases/paxmedica-announces-first-patent-allowance-for-suramin-intranasal-formulation-in-the-treatment-of-autism-spectrum-disorder-and-other-conditions/
43. Antifilarials and their mode of action - PubMed, accessed May 14, 2025, https://pubmed.ncbi.nlm.nih.gov/3297557/
44. Mechanistic insights into the activity of SARS-CoV-2 RNA polymerase inhibitors using single-molecule FRET | Nucleic Acids Research | Oxford Academic, accessed May 14, 2025, https://academic.oup.com/nar/article/53/8/gkaf351/8121653
45. Mechanistic insights into the activity of SARS-CoV-2 RNA polymerase inhibitors using single-molecule FRET - Oxford Academic, accessed May 14, 2025, https://academic.oup.com/nar/article-pdf/53/8/gkaf351/63026500/gkaf351.pdf
46. Suramin is a potent and selective inhibitor of Mycobacterium tuberculosis RecA protein and the SOS response: RecA as a potential target for antibacterial drug discovery - PubMed, accessed May 14, 2025, https://pubmed.ncbi.nlm.nih.gov/24722837/
47. Suramin is a potent and selective inhibitor of Mycobacterium tuberculosis RecA protein and the SOS response: RecA as a potential target for antibacterial drug discovery | Journal of Antimicrobial Chemotherapy | Oxford Academic, accessed May 14, 2025, https://academic.oup.com/jac/article/69/7/1834/2911194?login=true
48. Suramin, an experimental chemotherapeutic drug, activates the ..., accessed May 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC442984/
49. The effects of drugs on Onchocerca volvulus. 3. Trials of suramin at different dosages and a comparison of the brands Antrypol, Moranyl and Naganol - PubMed, accessed May 14, 2025, https://pubmed.ncbi.nlm.nih.gov/4881068/
50. The Effects of Drugs on Onchocerca volvulus, accessed May 14, 2025, https://apps.who.int/iris/bitstream/handle/10665/266592/PMC2554546.pdf?isAllowed=y&sequence=1
51. Recent developments in the treatment of onchocerciasis*, accessed May 14, 2025, https://iris.who.int/bitstream/handle/10665/265065/PMC2536340.pdf?sequence=1&isAllowed=y
52. Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells - PubMed, accessed May 14, 2025, https://pubmed.ncbi.nlm.nih.gov/1556185/
53. The anti-proliferative effect of suramin towards tamoxifen-sensitive ..., accessed May 14, 2025, https://pubmed.ncbi.nlm.nih.gov/9553667/
54. Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas, accessed May 14, 2025, https://pubmed.ncbi.nlm.nih.gov/11432894/
55. Phase I, Single-Dose Study to Assess the Pharmacokinetics and ..., accessed May 14, 2025, https://pubmed.ncbi.nlm.nih.gov/37457890/
56. Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial, accessed May 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5497533/
57. Suramin (injection route) - Mayo Clinic, accessed May 14, 2025, https://www.mayoclinic.org/drugs-supplements/suramin-injection-route/description/drg-20066167
58. Suramin - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Hepatic Dose | Drug Index | Pediatric Oncall, accessed May 14, 2025, https://www.pediatriconcall.com/drugs/suramin/185
59. A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis - PMC - PubMed Central, accessed May 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4001453/
60. Guidelines for the treatment of human African trypanosomiasis ..., accessed May 14, 2025, https://www.ncbi.nlm.nih.gov/books/NBK604893/
61. New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice - PubMed, accessed May 14, 2025, https://pubmed.ncbi.nlm.nih.gov/31879061/
63. PaxMedica Presents Clinical Data and New Analyses from a Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD) at the 2021 American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting - PR Newswire, accessed May 14, 2025, https://www.prnewswire.com/news-releases/paxmedica-presents-clinical-data-and-new-analyses-from-a-phase-2-trial-of-pax-101-iv-suramin-in-children-with-autism-spectrum-disorder-asd-at-the-2021-american-academy-of-child-and-adolescent-psychiatry-aacap-annual-meeting-301410356.html
64. PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal - ACCESS Newswire, accessed May 14, 2025, https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/paxmedica-announces-publication-of-its-autism-spectrum-disorder-phase-800332
65. Development of antiviral drugs for COVID-19 in 2025: unmet needs ..., accessed May 14, 2025, https://pubmed.ncbi.nlm.nih.gov/40007187/
66. Childhood hand, foot and mouth disease sequelae cohort study in Henan, China - PubMed Central, accessed May 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11751884/
67. Suramin Advanced Patient Information - Drugs.com, accessed May 14, 2025, https://www.drugs.com/cons/suramin-injection.html
68. Suramin: Parasite Uses, Warnings, Side Effects, Dosage - MedicineNet, accessed May 14, 2025, https://www.medicinenet.com/suramin/article.htm
69. Search Orphan Drug Designations and Approvals - FDA, accessed May 14, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=797220
70. WHO Model List of Essential Medicines - PAHO, accessed May 14, 2025, https://www.paho.org/sites/default/files/Updated_sixteenth_adult_list_en.pdf
71. WHO Model List of Essential Medicines - Wikipedia, accessed May 14, 2025, https://en.wikipedia.org/wiki/WHO_Model_List_of_Essential_Medicines
72. WHO EML 23rd List (2023) - World Health Organization (WHO), accessed May 14, 2025, https://apps.who.int/iris/rest/bitstreams/1518730/retrieve
73. PaxMedica today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used routinely to save lives in that region of Africa., accessed May 14, 2025, https://www.paxmedica.com/press-releases/paxmedica-receives-emergency-request-for-iv-suramin-from-african-health-ministry-for-use-in-treating-fatal-sleeping-sickness
74. Press Releases - PaxMedica, accessed May 14, 2025, https://www.paxmedica.com/press-releases
75. Recent developments in intranasal drug delivery of ... - Frontiers, accessed May 14, 2025, https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1463976/full
76. Research progress in brain-targeted nasal drug delivery - PMC, accessed May 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10828028/
77. A Study of Antioxidant, Antihyperlipidemic, and Anti-Glycation Effects of Alkylsulfonic Acids with Quinobenzothiazinyl Substituents: In Vitro and In Silico Investigations - PMC, accessed May 14, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12024154/